In the mid-2000s, the U.S. Patent Office (USPTO) determined that reexaminations would be more consistent and legally correct if performed by a centralized set of experienced and specially trained Examiners. As a result, the...more
The United States Patent and Trademark Office (USPTO) has proposed significant changes to patent fee structures for the 2025 fiscal year. These proposed changes mark a pivotal shift in the Office’s financial approach toward...more
Addressing the requirements for proof of prior art in inter partes review (IPR), the Patent Trial and Appeal Board (PTAB or Board) found that the petitioner failed to establish that certain documents cited qualified as...more
On August 24, 2015, the Patent Trial and Appeal Board (PTAB) declined institution of two petitions filed by Coalition For Affordable Drugs for Inter Partes Reviews (IPRs) of Acorda’s patents (U.S. Patent Nos: 8,007,826,...more
Yesterday the PTAB issued its first decision involving two of Kyle Bass’ IPR petitions targeting pharmaceutical companies, denying institution in both cases. Specifically, the PTAB denied institution of IPR2015-00720 and...more